All Posts By

Promis Neuro Admin

ProMIS Neurosciences to Present Preclinical Data on Alzheimer’s Disease Therapeutic Antibody PMN310 at Alzheimer’s Association International Conference

By | News

ProMIS Neurosciences to Present Preclinical Data on Alzheimer’s Disease Therapeutic Antibody PMN310 at Alzheimer’s Association International Conference PMN310 Shows Potential for Best in Class Amyloid-Beta Oligomer Selectivity TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 10, 2018– ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery…

Read More

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

By | News

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders ProMIS’ shareholders show overwhelming support for all resolutions TSX:PMN; OTCQB: ARFXF TORONTO, ON and CAMBRIDGE, MA, June 28, 2018 – ProMIS Neurosciences, Inc. (the “Corporation”), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today…

Read More

ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases

By | News

ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases Antibody Candidates Targeting Toxic Oligomers Implicated in Parkinson’s Disease and Amyotrophic Lateral Sclerosis (ALS) Advance to the Final Stage of ProMIS Discovery Platform TSX:PMN; OTCQB: ARFXF TORONTO, ONTARIO and CAMBRIDGE, MA – June 26, 2018 – ProMIS…

Read More